• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Medtronic wins FDA approval for Melody pulmonary valve

Medtronic wins FDA approval for Melody pulmonary valve

February 3, 2015 By Brad Perriello

Medtronic wins FDA approval for Melody pulmonary valve

Medtronic (NYSE:MDT) said today that it won pre-market approval from the FDA for its Melody transcatheter pulmonary valve, which is designed to delay the time between open heart surgeries in patients with a faulty connection from the heart to the lungs.

Fridley, Minn.-based Medtronic said the Melody TPV is designed for patients with a dysfunctional right ventricular outflow tract conduit caused by congenital heart disease. The PMA nod came after data from a trio of studies showed the valve’s effectiveness in delaying open heart procedures, according to a press release.

Medtronic won a humanitarian device exemption from the federal safety watchdog back in 2010. Congenital heart disease is the most common birth defect in the U.S., according to the release, affecting an estimated 40,000 patients annually; about 20% of those have disrupted blood flow from the right ventricular outflow tract to the pulmonary arteries. Some of those babies, implanted with a conduit designed to improve flow, are candidates for the Melody valve if their conduit fails but can still accommodate the implant, Medtronic said.

"The transition from HDE to PMA is an important regulatory milestone, which truly emphasizes the significant clinical benefit that the Melody TPV can bring to people with CHD by providing a therapy option that may reduce the number of open heart surgeries they need throughout their lifetime," heart valve therapies general manager Rhonda Robb said in prepared remarks. "Today’s approval reinforces Medtronic’s ongoing commitment to a congenital heart disease program by providing innovative and successful therapies to this underserved patient group.”

“The Melody valve has been a reliable option for patients suffering from CHD, and these data reinforce its strong performance since it was first introduced," added Dr. William Hellenbrand of the Yale School of Medicine. "This approval underscores the valve’s importance in treating this small patient population, who over their lifetime will face several open heart surgeries."

Medtronic said the 3 studies backing its successful PMA bid showed that 98% of patients implanted with the Melody valve were free from the need for open heart procedures for 1 year after implantation; in 1 of the trials, that rate was 91% after 5 years.

Filed Under: News Well, Pediatrics, Pre-Market Approval (PMA), Regulatory/Compliance, Replacement Heart Valves

More recent news

  • A new way to monitor glucose: Glucotrack explains 3-year CBGM implant technology
  • Dexcom continues advances in AI for CGM, type 2 diabetes awareness
  • Tandem continues to deliver more options, benefits for those with diabetes
  • Breaking: Sequel to launch twiist automated insulin delivery system next month
  • Dexcom shares U.S. report on CGM benefits for type 2 diabetes

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy